本帖最后由 老马 于 2013-3-13 13:43 编辑
' ~9 f( `) z1 o$ j$ x V- u, d1 C5 N; C% ^2 a! B" G) R
健择（吉西他滨）+顺铂+阿瓦斯汀
( b0 ?5 s1 z: n w- n# k Gemzar +Cisplatin + Avastin- A1 N! k, h# k# ?% _) h
http://annonc.oxfordjournals.org/content/21/9/1804.full. ?( s* w6 ^2 ]* o x9 y) c
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# i M6 V: E3 v# ?; b: Z; t$ ^! @Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. . t5 N& X) g! h: ?, q7 i
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) P# F9 c0 T/ d0 O9 f$ e
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 782)
; k7 u( }' {$ m1 i3 B华为网盘附件：& F& e# O5 O, i+ f- p) O
【华为网盘】ava.JPG
! I4 C1 Y: A4 n- ~- W/ P |
显身卡
